Molina Healthcare remains rated hold as it awaits clearer details on its cost structure post-Medicare Advantage Prescription Drug (MAPD) exit and market share recovery. The company’s exit from Medicare Advantage removes $1 billion in unprofitable revenue, improving business quality but reducing overall revenue. Molina reaffirmed its 2026 guidance of $42 billion in premium revenue and at least $5.00 adjusted EPS, with normalized earnings potential closer to $7.50 per share. Investors are looking ahead to the May 8 Investor Day for explicit cost reduction plans linked to the MAPD exit, which could prompt an upgrade to a buy rating.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
